Real Life Effectiveness in Patients With Not Optimally Controlled Asthma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00784953|
Recruitment Status : Completed
First Posted : November 4, 2008
Last Update Posted : November 10, 2015
A non-interventional study to explore actual asthma control status in real-life environment and to observe the efficacy after stepped-up to Symbicort SMART or various identical regimens.
The study will be implemented by screening asthmatic patients from respiratory clinics to identify those not optimally controlled and required stepping up the controllers to initiate, or to titrate dose of, ICS/LABA including Symbicort.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||842 participants|
|Official Title:||Real Life Effectiveness in Patients With Not Optimally Controlled Asthma: Symbicort SMART, or Other ICS/LABA With as Needed SABA|
|Study Start Date :||October 2008|
|Primary Completion Date :||May 2011|
|Study Completion Date :||May 2011|
Asthma patients who were partly controlled or uncontrolled, need to step up, or adjust dose of the controller medications to ICS/LABA
- Change in ACQ score from baseline to the mean of all available data from the follow up visits [ Time Frame: wk 4±1; wk 12~16 ]
- Change in the individual asthma control status & pulmonary function from enrollment [ Time Frame: wk 4±1; wk 12~16 ]
- Dose/usage of ICS/LABA and relievers & Patient compliance [ Time Frame: wk 4±1; wk 12~16 ]
- Medical resource utilization [ Time Frame: wk 4±1; wk 12~16; 6 month; 12 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00784953
|Study Director:||Robin Meng, MD, PhD||AstraZeneca Taiwan|
|Principal Investigator:||Jia-Horng Wang, MD||Taipei Veterans General Hospital, Taiwan|